Priya Singhal
Corporate Officer/Principal bei BIOGEN INC.
Vermögen: 1 Mio $ am 31.05.2024
Aktive Positionen von Priya Singhal
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 02.10.2023 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 31.12.2021 | 02.10.2023 |
Karriereverlauf von Priya Singhal
Ehemalige bekannte Positionen von Priya Singhal
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 | 01.01.2012 |
| LARIMAR THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 04.03.2019 | - |
Ausbildung von Priya Singhal
| Harvard T.H. Chan School of Public Health | Graduate Degree |
| University of Mumbai | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Indien | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Graduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Priya Singhal
- Erfahrung
